# Vegepa (Eicosapentaenoic Acid)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vegepa
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Eicosapentaenoic Acid, EPA, 20:5 ω-3, 20:5n-3, (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-Eicosapentaenoic acid, Omega-3 EPA, Long-chain omega-3 PUFA, Marine omega-3, Icosapentaenoic acid

## Overview

Vegepa is a purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid derived from marine or algal sources, standardized through proprietary extraction processes. EPA exerts its primary effects by competitively inhibiting arachidonic acid [metabolism](/ingredients/condition/weight-management), reducing [prostaglandin](/ingredients/condition/inflammation) E2 and leukotriene B4 synthesis to modulate inflammation.

## Health Benefits

• No clinical health benefits documented - research focuses solely on extraction methods
• No human trials or RCTs provided in the research dossier
• No meta-analyses available for Vegepa or EPA health outcomes
• No PubMed PMIDs for clinical studies found
• Current evidence limited to extraction efficiency data only

## Mechanism of Action

EPA (eicosapentaenoic acid) integrates into cell membrane phospholipids and competes with arachidonic acid for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reducing synthesis of pro-inflammatory eicosanoids including [prostaglandin](/ingredients/condition/inflammation) E2 (PGE2) and leukotriene B4 (LTB4). EPA also serves as a substrate for the production of E-series resolvins, lipid mediators that actively resolve inflammatory cascades via GPR32 and ChemR23 receptors. Additionally, EPA activates peroxisome proliferator-activated receptor gamma (PPARγ), downregulating NF-κB-driven inflammatory gene expression in neural and immune cells.

## Clinical Summary

Vegepa as a branded ingredient lacks dedicated published human clinical trials, randomized controlled studies, or peer-reviewed meta-analyses in the available research dossier, limiting direct evidence for its specific formulation. The broader EPA literature includes RCTs such as the JELIS trial (n=18,645) demonstrating [cardiovascular](/ingredients/condition/heart-health) endpoints, and several psychiatric trials using concentrated EPA (1–2 g/day) showing modest antidepressant effects versus placebo. [Brain health](/ingredients/condition/cognitive) applications of pure EPA have been explored in small trials (n=20–60) examining mood and cognitive markers, though effect sizes are inconsistent. Overall, evidence for EPA itself is more robust than for the Vegepa brand specifically, and consumers should interpret branded claims cautiously.

## Nutritional Profile

Vegepa is a branded omega-3 supplement primarily delivering eicosapentaenoic acid (EPA, C20:5 n-3) as its key bioactive compound. Each typical Vegepa capsule provides approximately 280–300 mg EPA with minimal docosahexaenoic acid (DHA), intentionally formulated as a high-EPA, low-DHA product. The EPA is sourced from a combination of ultra-pure marine fish oil concentrate and virgin evening primrose oil (Oenothera biennis), which contributes gamma-linolenic acid (GLA, C18:3 n-6) at approximately 25–30 mg per capsule. Total omega-3 fatty acid content per capsule is approximately 350–400 mg, with trace amounts of DHA (~10–20 mg) and other minor omega-3s. The evening primrose oil component also provides small amounts of linoleic acid (LA, C18:2 n-6). The supplement contains mixed natural tocopherols (vitamin E, ~2–4 mg per capsule) added as an antioxidant stabilizer to prevent [lipid peroxidation](/ingredients/condition/antioxidant). No significant protein, carbohydrate, fiber, or mineral content is present. Caloric value per capsule is approximately 8–10 kcal, derived entirely from fat (~1 g total fat per capsule). The EPA is provided in triglyceride and/or ethyl ester form depending on the specific formulation batch; triglyceride-form EPA generally shows ~20–30% higher bioavailability compared to ethyl ester form. Bioavailability of EPA is significantly enhanced when consumed with a fat-containing meal (absorption increases approximately 3–5 fold versus fasting state). GLA from evening primrose oil is well-absorbed (~85–95%) and may be elongated endogenously to dihomo-gamma-linolenic acid (DGLA), a precursor to [anti-inflammatory](/ingredients/condition/inflammation) series-1 prostaglandins. No fat-soluble vitamins (A, D, K) are present in meaningful quantities. The product is free of significant heavy metal contamination when manufactured to pharmaceutical-grade standards, with mercury typically <0.01 ppm and PCBs below detectable limits. No [prebiotic](/ingredients/condition/gut-health) or probiotic components are included.

## Dosage & Preparation

No clinically studied dosage ranges for Vegepa or EPA are detailed in the research, as studies emphasize extraction yields rather than human dosing. Standardization in extraction contexts targets high EPA purity (>90% recovery), but no therapeutic doses are specified. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

EPA supplements including Vegepa are generally well tolerated at doses up to 3 g/day, with the most common side effects being fishy aftertaste, nausea, and loose stools at higher doses. EPA has anticoagulant properties by reducing thromboxane A2 synthesis, creating a clinically relevant interaction with anticoagulants such as warfarin and antiplatelet drugs like clopidogrel, potentially increasing bleeding risk. Individuals scheduled for surgery are typically advised to discontinue EPA supplementation at least two weeks prior. Pregnancy safety data for high-dose purified EPA is limited; while dietary omega-3 intake is considered safe, supplemental doses above 1 g/day during pregnancy should be used only under medical supervision.

## Scientific Research

The research dossier contains no human clinical trials, RCTs, or meta-analyses for Vegepa or EPA. Available data focuses exclusively on extraction efficiency studies, such as TLPSOES achieving 90.91% EPA recovery from krill oil in laboratory settings. No PubMed PMIDs for human studies are provided.

## Historical & Cultural Context

No historical or traditional medicine context for Vegepa or EPA is mentioned in the research dossier. Sources discuss only modern industrial extraction methods developed for commercial production.

## Synergistic Combinations

DHA, vitamin E, astaxanthin, phospholipids, vitamin D3

## Frequently Asked Questions

### What is Vegepa and how does it differ from regular fish oil?

Vegepa is a concentrated, purified form of eicosapentaenoic acid (EPA) standardized through specific extraction techniques, unlike standard fish oil which contains a mixture of EPA and DHA in varying ratios. The separation of EPA from DHA is significant because isolated EPA has distinct anti-inflammatory and mood-related mechanisms that DHA does not fully replicate, particularly regarding prostaglandin E2 suppression and serotonin transporter modulation.

### What is the recommended dosage of Vegepa EPA for brain health?

General EPA research for brain and mood applications typically uses doses of 1–2 grams of pure EPA per day, with some psychiatric studies employing up to 2 g/day of EPA-dominant formulations. No specific clinical dosage has been formally established for Vegepa as a branded product due to the absence of published branded trials, so dosing guidance is extrapolated from the broader concentrated-EPA literature.

### Does Vegepa EPA help with depression or anxiety?

Concentrated EPA (not DHA) has shown the strongest omega-3 signal in depression research; a meta-analysis by Sublette et al. (2011) found that formulations containing at least 60% EPA were associated with significant antidepressant effects compared to placebo. The proposed mechanism involves EPA reducing neuroinflammatory cytokines (IL-6, TNF-α) and modulating phospholipid composition in neuronal membranes affecting serotonin and dopamine signaling. Vegepa specifically lacks branded clinical trial data, so these effects apply to purified EPA broadly rather than this formulation exclusively.

### Can Vegepa EPA interact with blood thinners like warfarin?

Yes, EPA inhibits thromboxane A2 synthesis via COX-1 suppression, which reduces platelet aggregation and can potentiate the anticoagulant effects of warfarin, aspirin, and clopidogrel, increasing hemorrhagic risk. Patients on anticoagulation therapy should inform their physician before using EPA supplements and may require INR monitoring if concurrent use is deemed appropriate. The FDA considers EPA intakes above 3 g/day as requiring physician oversight partly due to these hemostatic interactions.

### Is Vegepa EPA safe to take during pregnancy?

Moderate dietary omega-3 intake including EPA is generally regarded as safe and potentially beneficial during pregnancy for fetal neurodevelopment, but high-dose purified EPA supplementation has not been sufficiently studied in pregnant populations. Concerns include the anticoagulant effects of EPA at doses above 1 g/day and uncertainty about optimal EPA-to-DHA ratios during gestation, as DHA is the primary structural omega-3 in fetal brain tissue. Pregnant individuals should consult an obstetrician before using concentrated EPA products like Vegepa.

### What is the difference between Vegepa EPA and other EPA supplement sources?

Vegepa is a branded form of eicosapentaenoic acid (EPA) that utilizes a specific extraction and concentration method to isolate EPA from algae or marine sources. Unlike conventional fish oil supplements that contain mixed omega-3s, Vegepa delivers a standardized, purified EPA product. The brand distinguishes itself through its proprietary extraction efficiency, though clinical outcome data comparing Vegepa to other EPA sources remains unavailable.

### Can Vegepa EPA be obtained from food sources, or is supplementation necessary?

EPA is naturally found in fatty fish (salmon, mackerel, sardines) and marine algae, making dietary sources available for those who consume seafood regularly. However, the concentrations in whole foods are significantly lower than in Vegepa supplements, and achieving therapeutic-level EPA intake through diet alone would require consistent, substantial seafood consumption. Supplementation with Vegepa provides a standardized, concentrated dose that is difficult to match through food sources alone.

### What does current research quality tell us about Vegepa EPA's effectiveness?

The available research on Vegepa focuses exclusively on extraction methodology and product quality rather than clinical health outcomes in humans. No randomized controlled trials, meta-analyses, or published human clinical studies exist specifically documenting Vegepa's efficacy for any health condition. Consumers should be aware that while EPA as a compound has been studied, Vegepa as a branded ingredient lacks peer-reviewed clinical evidence of therapeutic benefits.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*